|
Gene: PPP2R3B |
Gene summary for PPP2R3B |
Gene summary. |
Gene information | Species | Human | Gene symbol | PPP2R3B | Gene ID | 28227 |
Gene name | protein phosphatase 2 regulatory subunit B''beta | |
Gene Alias | NYREN8 | |
Cytomap | X | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9Y5P8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
28227 | PPP2R3B | C38 | Human | Oral cavity | OSCC | 7.16e-03 | 3.81e-01 | 0.172 |
28227 | PPP2R3B | C46 | Human | Oral cavity | OSCC | 6.28e-11 | 2.63e-01 | 0.1673 |
28227 | PPP2R3B | C51 | Human | Oral cavity | OSCC | 1.42e-05 | 2.75e-01 | 0.2674 |
28227 | PPP2R3B | C57 | Human | Oral cavity | OSCC | 3.67e-02 | 1.69e-01 | 0.1679 |
28227 | PPP2R3B | LN22 | Human | Oral cavity | OSCC | 9.96e-04 | 5.78e-01 | 0.1733 |
28227 | PPP2R3B | LN46 | Human | Oral cavity | OSCC | 3.60e-06 | 3.04e-01 | 0.1666 |
28227 | PPP2R3B | SYSMH2 | Human | Oral cavity | OSCC | 1.93e-12 | 3.09e-01 | 0.2326 |
28227 | PPP2R3B | SYSMH3 | Human | Oral cavity | OSCC | 3.85e-15 | 5.38e-01 | 0.2442 |
28227 | PPP2R3B | SYSMH5 | Human | Oral cavity | OSCC | 1.23e-02 | 2.48e-01 | 0.0647 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | EOLP: Erosive Oral lichen planus | |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa051659 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0407114 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa041529 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
hsa0516514 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0407115 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415212 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP2R3B | SNV | Missense_Mutation | rs200453431 | c.1658C>T | p.Ala553Val | p.A553V | Q9Y5P8 | protein_coding | tolerated_low_confidence(1) | benign(0.01) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPP2R3B | SNV | Missense_Mutation | rs745317504 | c.778N>T | p.Arg260Cys | p.R260C | Q9Y5P8 | protein_coding | deleterious(0.04) | benign(0.159) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
PPP2R3B | SNV | Missense_Mutation | rs374748842 | c.400C>T | p.Arg134Cys | p.R134C | Q9Y5P8 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-FI-A2D6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP2R3B | SNV | Missense_Mutation | novel | c.865N>G | p.Ser289Gly | p.S289G | Q9Y5P8 | protein_coding | deleterious(0.05) | possibly_damaging(0.616) | TCGA-ZS-A9CG-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PPP2R3B | SNV | Missense_Mutation | novel | c.266N>G | p.Ser89Cys | p.S89C | Q9Y5P8 | protein_coding | tolerated(0.11) | benign(0.137) | TCGA-38-4631-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PPP2R3B | SNV | Missense_Mutation | c.1514A>T | p.Tyr505Phe | p.Y505F | Q9Y5P8 | protein_coding | tolerated(0.51) | benign(0.023) | TCGA-44-8117-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PPP2R3B | SNV | Missense_Mutation | c.1499N>T | p.Ser500Leu | p.S500L | Q9Y5P8 | protein_coding | deleterious(0) | possibly_damaging(0.815) | TCGA-55-8097-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PPP2R3B | SNV | Missense_Mutation | novel | c.1401N>G | p.Phe467Leu | p.F467L | Q9Y5P8 | protein_coding | deleterious(0) | possibly_damaging(0.542) | TCGA-22-4601-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
PPP2R3B | SNV | Missense_Mutation | novel | c.1489N>T | p.Pro497Ser | p.P497S | Q9Y5P8 | protein_coding | tolerated(0.06) | benign(0.03) | TCGA-58-8387-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP2R3B | SNV | Missense_Mutation | c.905N>T | p.Ala302Val | p.A302V | Q9Y5P8 | protein_coding | tolerated(0.07) | benign(0.062) | TCGA-CR-7368-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unspecific | Complete Response |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |